- Home
- PSNL vs ANVS Comparison
PSNL vs ANVS Comparison
Compare PSNL & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | ANVS |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 76.6M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PSNL | ANVS |
|---|---|---|
| Price | $16.33 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $12.20 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 3.5M | 997.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.58 | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,648,000.00 | N/A |
| Revenue This Year | $15.34 | N/A |
| Revenue Next Year | $41.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.96 | $1.22 |
| 52 Week High | $18.89 | $5.50 |
Technical Indicators
Market Signals| Indicator | PSNL | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 22.48 |
| Support Level | $7.62 | N/A |
| Resistance Level | $16.39 | $2.02 |
| Average True Range (ATR) | 0.77 | 0.10 |
| MACD | -0.16 | -0.06 |
| Stochastic Oscillator | 12.63 | 3.65 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.